Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question

摘要: After a hospital-wide formulary change resulted in the replacement of filgrastim with TBO-filgrastim for all on- and off-label indications, we performed retrospective comparison patients myeloma receiving 200 mg/m(2) melphalan autologous hematopoietic stem cell transplantation to see whether type growth factor used post-transplant made difference. One hundred eighty-two consecutive were studied, 91 immediately prior afterward. The CD34(+) dose was comparable, as other characteristics. Although overall time neutrophil recovery similar both groups, early engraftment (≤ 12 d) occurred more often (p = 0.05), late (≥ 14 less 0.09) filgrastim-treated patients. number documented infections significantly group. Day 100 mortality hospital stay two groups. These data indicate that there is no material difference between this clinical setting.